These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

648 related articles for article (PubMed ID: 26882078)

  • 1. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
    Fussner LA; Hummel AM; Schroeder DR; Silva F; Cartin-Ceba R; Snyder MR; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; William St Clair E; Tchao NK; Stone JH; Specks U;
    Arthritis Rheumatol; 2016 Jul; 68(7):1700-10. PubMed ID: 26882078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.
    Thompson GE; Fussner LA; Hummel AM; Schroeder DR; Silva F; Snyder MR; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Specks U
    Front Immunol; 2020; 11():2053. PubMed ID: 33013868
    [No Abstract]   [Full Text] [Related]  

  • 3. The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder DR; Kabat BF; Langford CA; Kallenberg CGM; Seo P; Spiera RF; St Clair EW; Fervenza FC; Stone JH; Monach PA; Specks U; Merkel PA;
    J Autoimmun; 2019 Dec; 105():102302. PubMed ID: 31320177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended versus standard azathioprine maintenance therapy in newly diagnosed proteinase-3 anti-neutrophil cytoplasmic antibody-associated vasculitis patients who remain cytoplasmic anti-neutrophil cytoplasmic antibody-positive after induction of remission: a randomized clinical trial.
    Sanders JS; de Joode AA; DeSevaux RG; Broekroelofs J; Voskuyl AE; van Paassen P; Kallenberg CG; Tervaert JW; Stegeman CA
    Nephrol Dial Transplant; 2016 Sep; 31(9):1453-9. PubMed ID: 27242368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD;
    Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
    Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA;
    Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis.
    McClure ME; Wason J; Gopaluni S; Tieu J; Smith RM; Jayne DR; Jones RB
    J Clin Rheumatol; 2019 Aug; 25(5):217-223. PubMed ID: 30896460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis.
    Damoiseaux J; Dähnrich C; Rosemann A; Probst C; Komorowski L; Stegeman CA; Egerer K; Hiepe F; van Paassen P; Stöcker W; Schlumberger W; Tervaert JW
    Ann Rheum Dis; 2009 Feb; 68(2):228-33. PubMed ID: 18375539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
    Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
    Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
    Bornstein G; Ben-Zvi I; Furie N; Grossman C
    Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
    van Dam LS; Dirikgil E; Bredewold EW; Ray A; Bakker JA; van Kooten C; Rabelink TJ; Teng YKO
    Nephrol Dial Transplant; 2021 Jul; 36(8):1408-1417. PubMed ID: 32601673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.
    Finkielman JD; Merkel PA; Schroeder D; Hoffman GS; Spiera R; St Clair EW; Davis JC; McCune WJ; Lears AK; Ytterberg SR; Hummel AM; Viss MA; Peikert T; Stone JH; Specks U;
    Ann Intern Med; 2007 Nov; 147(9):611-9. PubMed ID: 17975183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Cartin-Ceba R; Indrakanti D; Specks U; Stone JH; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Spiera RF; Monach PA; St Clair EW; Seo P; Tchao NK; Ytterberg SR; Brunetta PG; Song H; Birmingham D; Rovin BH;
    Arthritis Rheumatol; 2017 Jan; 69(1):169-175. PubMed ID: 27482943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
    Miloslavsky EM; Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Tchao NK; Ding L; Iklé D; Villareal M; Lim N; Brunetta P; Fervenza FC; Monach PA; Stone JH;
    Arthritis Rheumatol; 2015 Jun; 67(6):1629-36. PubMed ID: 25776953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease.
    Cao Y; Tian Z; Li W; Ma L; Yu Y; Ren W
    J Rheumatol; 2014 May; 41(5):916-22. PubMed ID: 24634200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of different commercial ELISA systems for the detection of anti-neutrophil cytoplasm antibodies in ANCA-associated vasculitides.
    Holle JU; Herrmann K; Gross WL; Csernok E
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S66-9. PubMed ID: 22512915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis.
    McAdoo SP; Hall A; Levy J; Salama AD; Pusey CD
    J Clin Rheumatol; 2012 Oct; 18(7):336-40. PubMed ID: 23047533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis.
    Segelmark M; Phillips BD; Hogan SL; Falk RJ; Jennette JC
    Clin Diagn Lab Immunol; 2003 Sep; 10(5):769-74. PubMed ID: 12965902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.